BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND NRAS, N-ras, 4893, ENSG00000213281, P01111, NRAS1
867 results:

  • 1. Epidemiological and clinicopathological features of KRAS, nras, BRAF mutations and MSI in Chinese patients with stage I-III colorectal cancer.
    Wang W; Wang R; Han X; Zhang W; Zhu L; Gu Y
    Medicine (Baltimore); 2024 Apr; 103(14):e37693. PubMed ID: 38579072
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. [colorectal adenocarcinoma with enteroblastic differentiation: a clinicopathological analysis of eight cases].
    Wang Q; Zhang Y; Tan C; Ni SJ; Huang D; Chang B; Sheng WQ; Wang L
    Zhonghua Bing Li Xue Za Zhi; 2024 Apr; 53(4):370-376. PubMed ID: 38556821
    [No Abstract]    [Full Text] [Related]  

  • 3. Concurrent nras-BRAF variants in metastatic colorectal cancer: a Tunisian case report.
    Douik H; Sahraoui G; Jemaà M; Doghri R; Charfi L; Mrad K
    Anticancer Drugs; 2024 Jun; 35(5):462-465. PubMed ID: 38451831
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Extended Enrichment for Ultrasensitive Detection of Low-Frequency Mutations by Long Blocker Displacement Amplification.
    Si Y; Wang X; Su X; Weng Z; Hu Q; Li Q; Fan C; Zhang DY; Wang Y; Luo S; Song P
    Angew Chem Int Ed Engl; 2024 May; 63(19):e202400551. PubMed ID: 38416545
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.
    Ciepiela I; Szczepaniak M; Ciepiela P; Hińcza-Nowak K; Kopczyński J; Macek P; Kubicka K; Chrapek M; Tyka M; Góźdź S; Kowalik A
    Sci Rep; 2024 Feb; 14(1):4619. PubMed ID: 38409377
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.
    Karapetis CS; Liu H; Sorich MJ; Pederson LD; Van Cutsem E; Maughan T; Douillard JY; O'Callaghan CJ; Jonker D; Bokemeyer C; Sobrero A; Cremolini C; Chibaudel B; Zalcberg J; Adams R; Buyse M; Peeters M; Yoshino T; de Gramont A; Shi Q
    Br J Cancer; 2024 May; 130(8):1269-1278. PubMed ID: 38402342
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. A Challenging Correlation between Tumor Cellularity and Somatic Variant Allele Fraction in Lung and colorectal cancers-Specimens of Low Tumor Percentage Should Be Analyzed with Caution.
    Zarabi SK; Zhai L; Cheng YW
    Biomolecules; 2024 Jan; 14(2):. PubMed ID: 38397405
    [No Abstract]    [Full Text] [Related]  

  • 8. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer.
    Shitara K; Muro K; Watanabe J; Yamazaki K; Ohori H; Shiozawa M; Takashima A; Yokota M; Makiyama A; Akazawa N; Ojima H; Yuasa Y; Miwa K; Yasui H; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Mori I; Yamanaka K; Hihara M; Soeda J; Misumi T; Yamamoto K; Yamashita R; Akagi K; Ochiai A; Uetake H; Tsuchihara K; Yoshino T
    Nat Med; 2024 Mar; 30(3):730-739. PubMed ID: 38347302
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Using tumor habitat-derived radiomic analysis during pretreatment
    Zhao H; Su Y; Wang Y; Lyu Z; Xu P; Gu W; Tian L; Fu P
    Cancer Imaging; 2024 Feb; 24(1):26. PubMed ID: 38342905
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. nras Mutant Dictates AHCYL1-Governed ER Calcium Homeostasis for Melanoma Tumor Growth.
    Cai C; Tu J; Najarro J; Zhang R; Fan H; Zhang FQ; Li J; Xie Z; Su R; Dong L; Arellano N; Ciboddo M; Elf SE; Gao X; Chen J; Wu R
    Mol Cancer Res; 2024 Apr; 22(4):386-401. PubMed ID: 38294692
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Genetic Polymorphisms and Tumoral Mutational Profiles over Survival in Advanced colorectal cancer Patients: An Exploratory Study.
    Cayún JP; Cerpa LC; Colombo A; Cáceres DD; Leal JL; Reyes F; Gutiérrez-Cáceres C; Calfunao S; Varela NM; Quiñones LA
    Curr Oncol; 2024 Jan; 31(1):274-295. PubMed ID: 38248103
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Clinical-Molecular characteristics and Post-Translational modifications of colorectal cancer in north China: Implications for future targeted therapies.
    Chi Y; Yuan H; Fan Q; Wang Z; Niu Z; Yu J; Yuan D
    Gene; 2024 Mar; 899():148134. PubMed ID: 38185290
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. colorectal Carcinoma With Sarcomatoid Components: Report of 15 Cases and Literature Review of an Exceedingly Rare Carcinoma Subtype.
    Golconda U; McHugh KE; Allende DS; Collins K; Henn P; Lacambra M; Bejarano PA; Groisman GM; Loughrey MB; Monappa V; Zhang X; Hornick JL; Gonzalez RS
    Am J Surg Pathol; 2024 Apr; 48(4):465-474. PubMed ID: 38155543
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Site specific genetic differences in colorectal cancer via Next-Generation-Sequencing using a multigene panel.
    Rencuzogullari A; Bisgin A; Erdogan KE; Gumus S; Yalav O; Boga I; Sonmezler O; Eray IC
    Ann Ital Chir; 2023; 94():605-611. PubMed ID: 38131395
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high colorectal cancer after Treatment Termination.
    Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
    Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Association Between RAS/BRAF Mutations and Complete Response Following Total Neoadjuvant Therapy in Patients with Rectal cancer: A Prospective Multicentered Study.
    Bedrikovetski S; Traeger L; Fitzsimmons T; Price TJ; Ruszkiewicz AR; Vather R; Sammour T
    Ann Surg Oncol; 2024 Mar; 31(3):1681-1689. PubMed ID: 38071720
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic colorectal cancer.
    Lee KW; Han SW; Kim TW; Ahn JB; Baek JY; Cho SH; Lee H; Kim JW; Kim JW; Kim TY; Hong YS; Beom SH; Cha Y; Choi Y; Kim S; Bang YJ
    Cancer Res Treat; 2024 Apr; 56(2):590-601. PubMed ID: 38062706
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Fucoxanthin Inhibits Development of Sigmoid colorectal cancer in a PDX Model With Alterations of Growth, Adhesion, and Cell Cycle Signals.
    Terasaki M; Tsuruoka K; Tanaka T; Maeda H; Shibata M; Miyashita K; Kanemitsu Y; Sekine S; Takahashi M; Yagishita S; Hamada A
    Cancer Genomics Proteomics; 2023 Dec; 20(6suppl):686-705. PubMed ID: 38035706
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Characteristic Mutational Damages in Gastric and colorectal Adenocarcinomas.
    Yermekova S; Orazgaliyeva M; Goncharova T; Rakhimbekova F; Kaidarova D; Shatkovskaya O
    Asian Pac J Cancer Prev; 2023 Nov; 24(11):3939-3947. PubMed ID: 38019254
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Prognostic and predictive biomarkers for anti-EGFR monoclonal antibody therapy in RAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
    Lu X; Li Y; Li Y; Zhang X; Shi J; Feng H; Yu Z; Gao Y
    BMC Cancer; 2023 Nov; 23(1):1117. PubMed ID: 37974093
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 44.